FORT WAYNE, Ind. -- (BUSINESS WIRE) -- Matrix-Bio, Inc., a leader in the field of cancer diagnostics using metabolomics, is a featured startup company at the 2013 Midwest E3 Summit in Indianapolis, September 25 and 26.
Sponsored by StepStone Business Partners, Indiana University Kelley School of Business and The Angel Resource Institute, the 2013 Midwest E3 Angel Investing Summit attracts entrepreneurs and angel investors interested in equipping themselves with the right tools for successful ventures and alternative investing.
Among the Summit’s highlights is a “competition” among 20 invited startup companies—including Matrix-Bio—that will compete for the chance to present to potential investors. Five companies will be selected to pitch their unique investment opportunities to qualified angel investors.
Matrix-Bio, Inc., was founded by former Purdue University chemistry professor Dan Raftery, Ph.D., M.B.A. Now headquartered in Fort Wayne, Ind., Matrix-Bio is developing diagnostic tests that use metabolite profiling to detect cancer earlier and with greater accuracy than current tests. In February, Matrix-Bio marked a significant milestone when it signed a global licensing agreement with Quest Diagnostics for the development of a clinical lab-developed blood test using metabolite profiling to detect breast cancer recurrence.
Matrix-Bio licensed additional metabolite biomarker technology from the Purdue Research Foundation last May to evaluate the commercial potential of diagnostic and monitoring tests for colon, esophageal, liver and pancreatic cancer; liver cancer in hepatitis C patients; and for predicting preoperative chemotherapy effectiveness for breast cancer treatment.
As part of his pitch, Matrix-Bio CEO Eric Beier will explain how advanced metabolite profiling identifies the unique metabolite signature of cancer cells in blood serum samples via a blood test, supporting early, more accurate cancer detection. Matrix-Bio’s VeraMarker™ BCR test detects the recurrence of breast cancer with twice the accuracy and 11 months earlier than the current CA 27-29 test, of which 3 million are performed in the United States annually. Matrix-Bio is now developing a colon cancer-monitoring test. According to the American Cancer Society, there are 102,480 new cases of colon cancer a year, causing some 50,830 deaths.
Matrix-Bio, Inc. is focused on the development and commercialization of metabolite profiling-based blood tests for early cancer detection, recurrence detection, and therapy monitoring that offer greater accuracy, convenience and lower cost than current testing methodologies. Visit www.matrix-bio.com.